Clinical Trial

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Study acronym: BaseCAR-01
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is to provide locally produced, bispecific CD19 CD20 CAR T cells to patients with B-cell lymphoma/leukemia who have no access to commercial CAR T cells or who have relapsed thereafter. The primary objective is to assess the safety of bispecific anti-CD19, anti- CD20 CAR T cell-therapies after lymphodepleting chemotherapy in patients with B cell malignancies with exhausted standard treatment options.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-03; most recent amendment 2025-12-17.
Trial Details
NCT Number NCT07166549
Lead Sponsor University Hospital, Basel, Switzerland
Conditions B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma, Bispecific Chimeric Antigen Receptor (CAR) T Cells, Relapsed or Refractory (r/r) B-cell Malignancies
Enrollment 12 participants
Start Date 2026-06
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2025-12-24